PharmAla Biotech was formed by a devoted team of biomanufacturing, regulatory and financial professionals, driven by the belief that MDMA shows clinical promise as a treatment for numerous disorders. We believe that the only way to advance the scientific research directly related to the medicinal use of MDMA is to ensure that researchers have a steady and accessible supply of clinical grade Active Pharmaceutical Ingredient (API).

PharmAla also believes that the base MDMA molecule can be improved upon. PharmAla researches and develops Novel Chemical Entities (NCEs) based on the MDXX class of molecules. Our goal is to improve these molecules’ safety properties, to allow their use to treat a diverse range of disorders.